Very well.
I was saying that we train students, and that is one of the reasons why companies working in the field of vaccination, such as GlaxoSmithKline or Aramis Biotechnologies, are able to remain in Quebec City.
So, this is just the beginning. VaxSynergy was created just a few months ago, and we anticipate that it will play an important role in facilitating the development of new vaccines and therapeutic proteins in Canada. Our survival will depend on government funding and the revenue generated by our activities. We hope to become financially self-sufficient within four or five years.